Geiger H J, Rietbrock N
Anaesthesist. 1976 Sep;25(9):405-17.
In a study of 233 patients from the department of surgery and anesthesiology taking digoxin preparations 64, per cent exhibit digoxin levels in the therapeutic range (0.6--1.5 ng/ml), 19 per cent had subtoxic concentrations ranged from 1.6--2.0 ng/ml and 7 per cent were in the toxic range (greater than 2 ng/ml). In patients treated with digoxin before admission to hospital subtherapeutic levels were most frequent. An average loading dose of digoxin 1 mg or more on one day may result in subtoxic and toxic digoxin levels on the second day, in patients receiving less than 1 mg digoxin daily an increasing frequency of plasma digoxin concentrations of 1.5 ng/ml or higher values was present on the third day. Averaged plasma digoxin concentrations were correlated with daily maintenance dose. There was, however, a wide individual variation in digoxin plasma concentrations. A low incidence of toxic digoxin plasma levels was observed in patients receiving a daily oral maintenance dose of 0.375 mg digoxin (Lanicor). For prophylactic digitalization of patients with normal renal and thyroid function the following schedules or statistical guidlines are proposed: Lanicor (bioavailability 60%): oral loading dose of 0.75 mg over two days, and then daily oral maintenance dose of 0.375 mg; Novodigal (bioavailability 80%): oral loading dose of 0.6 mg over two days and then daily oral maintenance dose of 0.3 mg; Digoxin i.v.: intravenous loading dose of 0.5 (0.4) mg over two days and then 0.25 (0.2) mg daily intravenous maintenance dose. For any patient needing treatment with digitalis glycosides therapy must be individual and dynamic. The reasons for toxic concentrations were frequently attributed to wrong dosage.
在一项对来自外科和麻醉科的233名服用地高辛制剂患者的研究中,64%的患者地高辛水平处于治疗范围(0.6 - 1.5纳克/毫升),19%的患者亚中毒浓度范围为1.6 - 2.0纳克/毫升,7%的患者处于中毒范围(大于2纳克/毫升)。入院前接受地高辛治疗的患者中,治疗水平以下最为常见。对于每日接受地高辛不足1毫克的患者,在一天给予平均负荷剂量1毫克或更多地高辛时,第二天可能会出现亚中毒和中毒的地高辛水平;在第三天,血浆地高辛浓度达到1.5纳克/毫升或更高值的频率增加。平均血浆地高辛浓度与每日维持剂量相关。然而,地高辛血浆浓度存在很大的个体差异。在每日口服维持剂量为0.375毫克地高辛(Lanicor)的患者中,观察到中毒地高辛血浆水平的发生率较低。对于肾功能和甲状腺功能正常的患者进行预防性洋地黄化,建议采用以下方案或统计指南:Lanicor(生物利用度60%):分两天口服负荷剂量0.75毫克,然后每日口服维持剂量0.375毫克;Novodigal(生物利用度80%):分两天口服负荷剂量0.6毫克,然后每日口服维持剂量0.3毫克;静脉用地高辛:分两天静脉注射负荷剂量0.5(0.4)毫克,然后每日静脉维持剂量0.25(0.2)毫克。对于任何需要使用洋地黄苷治疗的患者,治疗必须个体化且动态化。中毒浓度的原因常常归因于剂量错误。